Background: Extracranial Carotid Artery Aneurysm is considered a therapeutic and diagnostic challenge. In an unprecedented way in the literature, we？describe an aneurysm originating from the Catastrophic Antiphospholipid Syndrome. Case Presentation: A 25-year-old male patient came to the Emergency Room of the ABC University Hospital in Sao Bernardo do Campo referring to bilateral neck pain for 1 month, associated with carotid aneurysms. Due to the severity and urgency of the clinical condition, immediate surgical therapy was performed without a definitive etiological diagnosis. The initial morphological analysis of the carotid artery suggested a diagnosis of Polyarteritis Nodosa. After anamnesis, physical examination, the use of a specific primary vasculitis？algorithm, and a review of the pathological anatomy was requested, which showed bilateral carotid aneurysms secondary to catastrophic antiphospholipid syndrome. Conclusion: It remains evident that Extracranial Carotid Artery Aneurysm-
References
[1]
El-Sabrout, R. and Cooley, D.A. (2000) Extracranial Carotid Artery Aneurysms: Texas Heart Institute Experience. Journal of Vascular Surgery, 31, 702-712.
https://doi.org/10.1067/mva.2000.104101
[2]
Attigah, N., Külkens, S., Zausig, N., Hansmann, J., Ringleb, P., et al. (2009) Surgical Therapy of Extracranial Carotid Artery Aneurysms: Long-Term Results over a 24-Year Period. European Journal of Vascular and Endovascular Surgery, 37, 127-133.
https://doi.org/10.1016/j.ejvs.2008.10.020
[3]
Park, K.M. and Kim, D.I. (2016) Bilateral Extracranial Carotid Artery Aneurysms Treated by Staged Surgical Repair. EJVES Short Reports, 36, 13-15.
https://doi.org/10.1016/j.ejvssr.2016.11.002
[4]
Jennette, J.C., Falk, R.J., Bacon, P.A., Basu, N., Cid, M.C., Ferrario, F., et al. (2013) 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism, 65, 1-11. https://doi.org/10.1002/art.37715
[5]
Bezerra, A.S., Polimanti, A.C., Oliveira, R.A., Fürst, R.V.C., Criado, P.R. and Corrêa, J.A. (2020) Early Diagnosis and Treatment of Leukocytoclastic Vasculitis: Case Report. Jornal Vascular Brasileiro, 19, Article ID: e20180072.
https://doi.org/10.1590/1677-5449.190093
[6]
Jennette, J.C., Falk, R.J., Andrassy, K., Bacon, P.A., Churg, J., et al. (1994) Nomenclature of Systemic Vasculitides. Proposal of an International Consensus Conference. Arthritis & Rheumatism, 37, 187-192. https://doi.org/10.1002/art.1780370206
[7]
Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, L.R., et al. (2006) International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome (APS). Journal of Thrombosis and Haemostasis, 4, 295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
[8]
Cervera, R., Rodríguez-Pintó, I., Colafrancesco, S., Conti, F., Valesini, G., et al. (2014) 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmunity Reviews, 13, 699-707.
https://doi.org/10.1016/j.autrev.2014.03.002
[9]
Bucciarelli, S., Espinosa, G., Cervera, R., Erkan, D., Gómez-Puerta, J.A., et al. (2006) Mortality in the Catastrophic Antiphospholipid Syndrome: Causes of Death and Prognostic Factors in a Series of 250 Patients. Arthritis & Rheumatism, 54, 2568-2576.
https://doi.org/10.1002/art.22018
[10]
Zuily, S., de Laat, B., Guillemin, F., Kelchtermans, H., Magy-Bertrand, N., et al. (2020) Anti-Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study. The Journal of Applied Laboratory Medicine, 5, 1242-1252. https://doi.org/10.1093/jalm/jfaa072
[11]
Bezerra, A.S., Wroclawski, C.K., Lorber, G.R. and Filho, C.C. (2021) Secondary Vasculopathy Due to Catastrophic Antiphospholipid Syndrome. Hematology, Trans- fusion and Cell Therapy. (In Press) https://doi.org/10.1016/j.htct.2021.09.012
[12]
Cervera, R., Piette, J.C., Font, J., Khamstha, M.A., Shoenfeld, Y., et al. (2002) Antiphos- pholipid Syndrome: Clinical and Immunologic Manifestations and Patterns of Disease Expression in a Cohort of 1,000 Patients. Arthritis & Rheumatism, 46, 1019- 1027. https://doi.org/10.1002/art.10187
[13]
Abreu, J.S.F., Santos, A.O., Medeiros, J.N. and Gouvea, C.P. (2018) Models for Releasing the Lupus Anticoagulant Test. Jornal Brasileiro de Patologia e Medicina Labo- ratorial, 54, 153-157.
[14]
Ortel, T.L., Erkan, D. and Kitchens, C.S. (2015) How I Treat Catastrophic Trombotic Syndromes. Blood, 126, 1285-1293. https://doi.org/10.1182/blood-2014-09-551978
[15]
Cervera, R. (2010) Update on the Diagnosis, Treatment, and Prognosis of the Catastrophic Antiphospholipid Syndrome. Current Rheumatology Reports, 12, 70-76.
https://doi.org/10.1007/s11926-009-0073-6
[16]
Zar, T. and Kaplan, A.A. (2008) Predictable Removal of Anticardiolipin Antibody by Therapeutic Plasma Exchange (TPE) in Catastrophic Antiphospholipid Antibody Syndrome (CAPS). Clinical Nephrology, 70, 77-81.
https://doi.org/10.5414/CNP70077
[17]
Schmidt-Tanguy, A., Voswinkel, J., Henrion, D., Subra, J.F., Loufrani, L., et al. (2013) Antithrombotic Effects of Hydroxychloroquine in Primary Antiphospholipid Syndrome Patients. Journal of Thrombosis and Haemostasis, 11, 1927-1929.
https://doi.org/10.1111/jth.12363
[18]
Berman, H., Rodríguez-Pintó, I., Cervera, R., Morel, N., Costedoat-Chalumeau, N., et al. (2013) Rituximab Use in the Catastrophic Antiphospholipid Syndrome: Descriptive Analysis of the CAPS Registry Patients Receiving Rituximab. Autoimmunity Reviews, 12, 1085-1090. https://doi.org/10.1016/j.autrev.2013.05.004
[19]
Shapira, I., Andrade, D., Allen, S.L. and Salmon, J.E. (2012) Brief Report: Induction of Sustained Remission in Recurrent Catastrophic Antiphospholipid Syndrome via Inhibition of Terminal Complement with Eculizumab. Arthritis & Rheumatism, 64, 2719-2723. https://doi.org/10.1002/art.34440
[20]
Erkan, D. and Salmon, J.E. (2016) The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome. Turkish Journal of Haematology, 33, 1-7. https://doi.org/10.4274/tjh.2015.0197
